Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2021 March Pharma News Flumatinib induces higher rates of deep responses compared to imatinib in CML Read more
2021 March Clinical practice Validation of the revised 2017 European LeukemiaNet genetic risk stratification for AML Read more
Top
